People

Chairman of the Supervisory Board

Dr. Manfred Wolter serves as Chairman of the Supervisory Board. Ministerialdirigent Dr. Manfred Wolter is Head of the Department “Innovation, Research, Technology, Digitalisation” at the Bavarian Ministry of Economic Affairs, Energy and Technology.

Deputy Director of the Board, StemCellRegMed Foundation

Johanna Boeck-Heuwinkel serves as Deputy Director of the StemCellRegMed Foundation Board. She is Attorney of Law & Senior Consultant. Her experience comprises realization of strategic academic-corporate partnerships in the public sector and 15 years support of scientist entrepreneurs during the foundation phase of technology start-ups in the metropolitan areas of Düsseldorf, Hamburg and Munich.

Director of the Board, StemCellRegMed Foundation

Prof. Dr. Horst Domdey serves as Director of the StemCellRegMed Foundation Board. Horst Domdey is Managing Director of BioM – Biotechnology Cluster Management for Munich & Bavaria.

Director Board of Trustees, StemCellRegMed Foundation

Prof. Dr. Hans R. Schöler is founding team member and serves as Director of the Board of Trustees of the StemCellRegMed Foundation. Hans Schöler is Director of the Department of Cell and Developmental Biology at the Max-Planck-Institute for Molecular Biomedicine in Münster, Germany.
Dr. Schöler studied Biology at Heidelberg University and received his PhD at the Center for Molecular Biology Heidelberg (ZMBH). He was Research Group Leader with Boehringer Mannheim and Scientific Fellow at the Max-Planck-Institute for Biophysical Chemistry in Göttingen before he headed a research group at the European Molecular Biology Laboratory (EMBL) in Heidelberg. Dr. Schöler received his Venia Legendi in Molecular Biology at the Biological Faculty of Heidelberg University and was then appointed Professor, the Marion Dilley and David George Jones Chair for Reproductive Medicine and Director of the Center for Animal Transgenesis and Germ Cell Research (CATGCR) at the University of Pennsylvania (PENN), School of Veterinary Medicine, Department of Animal Biology in Philadelphia, USA. He still serves at PENN as an Adjunct Professor of Biochemistry. He is also a Professor at the Medical Faculty of the Westphalian Wilhelms University in Münster and Adjunct Professor at the Hanover Medical School (MHH) as well as a Distinguished Professor at Konkuk University, Seoul, South Korea. In 2010 the Ulsan National Institute of Science and Technology (UNIST) opened the Hans Schöler Stem Cell Research Center (HSSCRC) in Ulsan, South Korea.

Chief Scientific Advisor of ISAR Bioscience

Prof. Dr. Dr. h.c. Christian Haass serves as Chief Scientific Advisor. He is Head of the Department of Metabolic Biochemistry at the Biomedical Center of Ludwig-Maximilians-University Munich and Speaker of the German Center for Neurodegenerative Disorders (DZNE) and of the Munich Cluster of Systems Neurology (SyNergy).
Dr. Haass graduated in Molecular Biology at the University of Heidelberg, Germany. He was a postdoc and assistant professor of Neurology at Harvard Medical School in the institute of Dr. Dennis Selkoe. He received a number of prestigious awards, among them the Gottfried Wilhelm Leibniz-Award of the Deutsche Forschungsgemeinschaft, the Potamkin Award of the American Academy of Neurology, an ERC advanced grant, and most recently the Brain prize.

CEO of ISAR Bioscience

Dr. Ulrich C. Gerth is Founding Director and serves as Chief Executive Officer. He is a Science Manager and has a track record as Technology Transfer and Innovation Manager with strategic and operational responsibilities. Previously he served as Business Analyst at the global consulting firm Ernst & Young, as a Financial Analyst for equity markets and corporate finance at HypoVereinsbank, Senior Analyst at a Federal Government Agency, New Products Planning Manager at Wyeth Pharma, and Deputy Head of Business Development Med- and Biotech at the fonds management service provider IPB AG for Deutsche Bank AG. Dr. Gerth was designated Managing Director of CARE (Center for Advanced Regenerative Engineering) to build a translational research reference center for applied stem cell research, which he successfully launched as ISAR Bioscience in 2018. He received his DPhil in molecular immunology from Oxford University at the MRC Weatherall Institute of Molecular Medicine.

CTO of ISAR Bioscience

Dr. Andreas Hochheimer is founding team member and serves as Chief Technology Officer and Head of R&D & Translational Science. He served previously at AMGEN heading HTS drug discovery of pharmaceutical targets in neurodegenerative, inflammatory and metabolic disorders as well as oncology. He is University Lecturer in Biochemistry/Molecular Cell Biology and successfully established translational R&D programs as well as corporate-academic partnerships. Prior to AMGEN, he led the Human-Taste-Cell discovery research and business development program at BRAIN AG to implement human taste cells for taste modulator screening and to investigate human taste cell physiology. Dr. Hochheimer received a degree in Biology and Ph.D. in Microbiology from Philipps-University Marburg. He was Professor in Biochemistry at Ludwig-Maximilians-University Munich and further received Venia Legendi and had faculty appointments at Technical University Darmstadt and University Regensburg.